Elanix Biotechnologies AG (ELN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Elanix Biotechnologies AG (ELN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9412
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Elanix Biotechnologies AG (Elanix Biotechnologies), formerly Porta Systems AG, is a tissue regeneration company that develops and commercializes products for acute wound care, dermatological and gynecological applications. The company offers GYNrepair cream and SKINrepair cream for skin care applications. It develops bioresorbable and bioactive skin dressings derived from progenitor skin fibroblasts containing growth factors and cytokines to provide protection and accelerated healing for burns, trauma and plastic surgery. Elanix Biotechnologies also produces validated progenitor skin cells used in drug discovery, toxicity testing, and cosmetic applications. The company has operations in Germany and Switzerland. Elanix Biotechnologies is headquartered in Wiesbaden, Germany.

Elanix Biotechnologies AG (ELN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Elanix Biotechnologies AG, Medical Devices Deals, 2012 to YTD 2018 9
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Elanix Biotech Acquires Third Cell Free Protein Complex Product 11
Equity Offering 12
Elanix Biotech Raises USD1.3 Million in Private Placement of Shares 12
Acquisition 13
Elanix to Acquire Inno 4 Cell 13
Elanix Biotechnologies AG – Key Competitors 14
Elanix Biotechnologies AG – Key Employees 15
Elanix Biotechnologies AG – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Financial Announcements 17
Sep 29, 2017: Elanix Biotechnologies Announces First Half 2017 Financial Results 17
Corporate Communications 18
May 29, 2018: Elanix Biotechnologies Appoints Egon Minar As COO And CFO 18
Product News 19
May 31, 2017: Elanix Biotechnologies Starts EU Commercialization of GYNrepair Cream for Women’s Intimate Relief 19
Other Significant Developments 20
Jan 23, 2018: Elanix Biotechnologies Appoints Baader Bank as a New Designated Sponsor and goetzpartners securities for Corporate Broking 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elanix Biotechnologies AG, Deals By Therapy Area, 2012 to YTD 2018 8
Elanix Biotechnologies AG, Medical Devices Deals, 2012 to YTD 2018 9
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Elanix Biotech Acquires Third Cell Free Protein Complex Product 11
Elanix Biotech Raises USD1.3 Million in Private Placement of Shares 12
Elanix to Acquire Inno 4 Cell 13
Elanix Biotechnologies AG, Key Competitors 14
Elanix Biotechnologies AG, Key Employees 15

List of Figures
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elanix Biotechnologies AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Elanix Biotechnologies AG, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Elanix Biotechnologies AG (ELN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Montana Tech Components AG:企業の戦略・SWOT・財務情報
    Montana Tech Components AG - Strategy, SWOT and Corporate Finance Report Summary Montana Tech Components AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Airservices Australia:企業の戦略的SWOT分析
    Airservices Australia - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Theratechnologies Inc (TH):製薬・医療:M&Aディール及び事業提携情報
    Summary Theratechnologies Inc (Theratechnologies) is a pharmaceutical company that focuses on the discovery and development of drugs for metabolic disorders. The company develops therapeutic peptide products, with an emphasis on growth releasing factor (GRF) peptides. Its lead products include Egrif …
  • Hochdorf Holding AG (HOCN):企業の財務・戦略的SWOT分析
    Hochdorf Holding AG (HOCN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Orliman SLU-医療機器分野:企業M&A・提携分析
    Summary Orliman SLU (Orliman), a subsidiary of The Riverside Company is a medical device company that develops and manufactures orthopedic products. The company's products include stabilizers, immobilizers, lumbosacral back supports, abdominal bands, abdominal belt, shoulder supports, truss, corsets …
  • Vale Canada Ltd:企業の戦略・SWOT・財務分析
    Vale Canada Ltd - Strategy, SWOT and Corporate Finance Report Summary Vale Canada Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tokyo Electron Device Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Electron Device Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Electron Device Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Banco Bilbao Vizcaya Argentaria SA:戦略・SWOT・企業財務分析
    Banco Bilbao Vizcaya Argentaria SA - Strategy, SWOT and Corporate Finance Report Summary Banco Bilbao Vizcaya Argentaria SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Groupe Sodiaal:企業の戦略・SWOT・財務情報
    Groupe Sodiaal - Strategy, SWOT and Corporate Finance Report Summary Groupe Sodiaal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Southern Petrochemical Industries Corp Ltd (SPIC):企業の財務・戦略的SWOT分析
    Summary Southern Petrochemical Industries Corp Ltd (SPIC) is a chemical company that manufactures fertilizers for agriculture. The company offers products such as chemical fertilizer, organic and water soluble fertilizers, plant growth regulators, micro nutrients, and industrial products. Its chemic …
  • Shinva Medical Instrument Co Ltd (600587):企業の財務・戦略的SWOT分析
    Shinva Medical Instrument Co Ltd (600587) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Intercontinental Hotels Group Plc:企業の戦略・SWOT・財務分析
    Intercontinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report Summary Intercontinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • British Arab Commercial Bank plc:企業の戦略的SWOT分析
    British Arab Commercial Bank plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Blue Cross and Blue Shield Association:企業の戦略的SWOT分析
    Blue Cross and Blue Shield Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Selex Gruppo Commerciale S.p.A.:企業の戦略・SWOT・財務情報
    Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • MEAG Munich Ergo AssetManagement GmbH:電力:M&Aディール及び事業提携情報
    Summary MEAG Munich Ergo AssetManagement GmbH (MEAG Munich), a subsidiary of Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft (Munich Re) is an asset management company that manages assets of Munich Re and ERGO Insurance Group and its affiliates. The company offers services such as asset …
  • Principia Biopharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Principia Biopharma Inc (Principia Biopharma) is a biopharmaceutical company that designs and develops oral small molecule drug therapies. The company’s proprietary Tailored Covalency technology helps to develop portfolio of drugs such as Bruton's tyrosine kinase (BTK) inhibitor, Interleukin …
  • Calfrac Well Services Ltd (CFW):企業の財務・戦略的SWOT分析
    Calfrac Well Services Ltd (CFW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • FBN Bank (UK) Ltd:企業の戦略・SWOT・財務情報
    FBN Bank (UK) Ltd - Strategy, SWOT and Corporate Finance Report Summary FBN Bank (UK) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • UPL Ltd (UPL):企業の財務・戦略的SWOT分析
    UPL Ltd (UPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆